HIGHLIGHT
Cavsamir

Cavsamir

sevelamer

Manufacturer:

Dr. Reddy's Lab

Distributor:

DKSH
Concise Prescribing Info
Contents
Sevelamer carbonate
Indications/Uses
Control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis, or chronic kidney disease (CKD) not on dialysis w/ serum P ≥1.78 mmol/L.
Dosage/Direction for Use
Patient not taking phosphate binder Initially 1 or 2 tab tds based on serum P level. CKD patient on dialysis or patient switching from sevelamer HCl Max: 14 g daily.
Administration
Should be taken with food: Swallow whole, do not chew/crush/divide.
Contraindications
Hypersensitivity. Hypophosphataemia; bowel obstruction.
Special Precautions
Dysphagia, swallowing disorders, severe GI motility disorders including untreated or severe constipation or major GI tract surgery. Monitor bicarbonate, Cl levels during treatment; additional monitoring of fat-soluble vit & folic acid in patients undergoing peritoneal dialysis. Assess vit A, D, E & K status regularly. Not recommended in patients w/ CKD not on dialysis w/ serum P <1.78 mmol/L. Pregnancy & lactation. Not recommended in childn <18 yr.
Adverse Reactions
Nausea, vomiting, upper abdominal pain, constipation. Diarrhoea, dyspepsia, flatulence, abdominal pain.
Drug Interactions
Reduced bioavailability of cyclosporine, tacrolimus, levothyroxine. Increased phosphate levels w/ proton-pump inhibitors eg, omeprazole, pantoprazole or lansoprazole. Anti-arrhythmics, anti-seizure medications, ciprofloxacin, mycophenolate mofetil.
ATC Classification
V03AE02 - sevelamer ; Belongs to the class of drugs used in the treatment of hyperkalemia and hyperphosphatemia.
Presentation/Packing
Form
Cavsamir FC tab 800 mg
Packing/Price
270's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in